Ambalal Sarabhai Enterprises Limited (BOM:500009)
India
· Delayed Price · Currency is INR | Market Cap | 2.48B |
| Revenue (ttm) | 2.03B |
| Net Income (ttm) | 104.58M |
| Shares Out | 76.63M |
| EPS (ttm) | 1.36 |
| PE Ratio | 23.77 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,172 |
| Average Volume | 93,738 |
| Open | 35.10 |
| Previous Close | 34.76 |
| Day's Range | 33.00 - 35.16 |
| 52-Week Range | 23.12 - 40.44 |
| Beta | -0.14 |
| RSI | 61.10 |
| Earnings Date | May 22, 2026 |
About BOM:500009
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Am... [Read more]
Financial Performance
In fiscal year 2025, BOM:500009's revenue was 1.97 billion, an increase of 13.20% compared to the previous year's 1.74 billion. Earnings were 49.31 million, a decrease of -13.20%.
Financial StatementsNews
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics Inc. (NASDAQ: CODX) on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd , to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakista...